Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

@article{Nagai2002OpenlabelCU,
  title={Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.},
  author={Sonoko Nagai and Kunio Hamada and Michio Shigematsu and Masayosi Taniyama and Shitotomo Yamauchi and Takateru Izumi},
  journal={Internal medicine},
  year={2002},
  volume={41 12},
  pages={1118-23}
}
OBJECTIVE We attempted to evaluate the feasibility (therapeutic efficacy, tolerance, and clinical courses after treatment) of pirfenidone, an anti-fibrotic drug for patients with chronic pulmonary fibroses such as idiopathic pulmonary fibrosis (IPF). METHODS Open-label one-year treatment for compassionate-use. PATIENTS OR MATERIALS Oral pirfenidone (40 mg/kg body weight) was administered to 8 patients with advanced IPF and 2 with interstitial pneumonia associated with diffuse systemic… CONTINUE READING